New cancer shot slashes risk of death and return for melanoma patients

Merck and Moderna announced on Thursday that a personalized mRNA vaccine against melanoma has shown strong results in a late stage trial. The companies said the treatment reduced the risk of death or cancer recurrence by 42 percent. This figure compares the new vaccine combined with standard care to standard care alone. Melanoma is known as the deadliest form of skin cancer. The new option offers a significant advance for patients fighting this disease.

The trial involved 1,137 patients. These individuals had stage IIB to IV melanoma. Their tumors had been surgically removed before they entered the study. Researchers randomly assigned the patients to two groups. One group received a combination treatment. This included the personalized mRNA vaccine alongside a standard therapy. The other group received only the standard therapy. The standard treatment used in this study was Merck's monoclonal antibody drug Keytruda.

The standard treatment alone served as the control group. The combination group received the vaccine in addition to Keytruda. The results showed a clear difference in outcomes between the two groups. The 42 percent reduction in risk is a substantial improvement. It suggests that adding the personalized vaccine to existing therapy can help keep the cancer at bay. This approach targets the specific needs of individual patients.

Stéphane Bancel is the chief executive officer of Moderna. He issued a statement about the results. He said the company believed mRNA technology could lead to treatments matched to each patient's tumor from the start. He described the trial results as a defining moment for that vision. Bancel added that the findings show what is possible when medicines are rethought. He said the results reinforce the conviction that mRNA can fundamentally change cancer treatment.

The partners are already moving forward with regulatory steps. They are engaging with authorities to seek approval for the vaccine. This process is underway following the announcement of the top line results. The companies had reported success in August but held back details. They waited for the data to be presented at a scientific conference. The full data has been accepted for publication in the New England Journal of Medicine.

The intended presentation was part of the European Society of Medical Oncology meeting. This conference is currently taking place in Madrid, Spain. The data was scheduled to be shown on Saturday. However, an oncology news site reported the results early. This broke the embargo that the companies had in place. Consequently, Merck and Moderna released the key findings ahead of the scheduled presentation.

The success of this vaccine boosts broader hopes for cancer therapy. It suggests that individualized medicines can be a new paradigm. mRNA vaccines are not just for infectious diseases. They may play a major role in treating cancer in the future. The ability to tailor a vaccine to a specific tumor is a key part of this new approach. This study provides concrete evidence that this method works in a large patient group.

The trial results are being watched closely by the medical community. A 42 percent reduction in death or recurrence is a strong outcome. It highlights the potential of combining new technology with proven treatments. Keytruda remains a cornerstone of cancer care. Adding a personalized vaccine to this regimen may become a standard option for suitable patients. The next steps will involve finalizing the regulatory process and determining how widely the vaccine will be available.

The announcement marks a significant milestone in the fight against skin cancer. Patients with melanoma often face a high risk of recurrence even after surgery. This new option offers a way to lower that risk significantly. The use of mRNA technology in this context is a notable development. It shows that the same science behind other vaccines can be applied to complex diseases like cancer. The medical world is now waiting to see how quickly this treatment can reach more patients.